New antioxidants targeting mitochondria to treat preeclampsia
Mitochondria-targeting Novel Cationic Hydrazone Antioxidants for the Treatment of Preeclampsia
This study is looking at new ways to help pregnant women with preeclampsia by creating special antioxidants that can target the energy centers in their cells, aiming to reduce stress and improve blood flow during pregnancy.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Massachusetts Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10730652 on NIH RePORTER |
What this research studies
This research focuses on developing innovative antioxidants specifically designed to target mitochondria in order to treat preeclampsia, a serious pregnancy complication characterized by high blood pressure. The approach involves creating novel cationic organofluorine hydrazones that enhance antioxidant potential and improve delivery to mitochondria. By combining specific structural features, the researchers aim to create compounds that can effectively reduce oxidative stress and improve blood flow in pregnant women affected by preeclampsia. The study will involve screening these compounds for their antioxidant activity through various biochemical assays.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant women diagnosed with preeclampsia.
Not a fit: Patients who are not pregnant or those without a diagnosis of preeclampsia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for preeclampsia, potentially reducing risks for both mothers and their babies.
How similar studies have performed: While the approach of using mitochondria-targeted antioxidants is innovative, similar antioxidant therapies have shown promise in other conditions, suggesting potential for success in this area.
Where this research is happening
Boston, United States
- University of Massachusetts Boston — Boston, United States (Active)
Researchers
- Principal investigator: Torok, Marianna — University of Massachusetts Boston
- Study coordinator: Torok, Marianna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.